FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2300936242> ?p ?o ?g. }

• W2300936242 endingPage "e0151809" @default.
• W2300936242 startingPage "e0151809" @default.
• W2300936242 abstract "Background To investigate the diagnostic and prognostic performances of 18F-FDG PET/CT measures of metabolic tumour burden in patients with neurofibromatosis type-1 (NF1), suspect of malignant transformation. Methods This retrospective study included 49 patients (15–60 years old, 30 women) with a diagnosis of NF1, followed in our Reference Centre for Rare Neuromuscular Diseases, who presented clinical signs of tumour progression (pain, neurological deficit, tumour growth). Quantitative metabolic parameters were measured on 149 tumoral targets, using semi-automatic software and the best cut off values to predict transformation was assessed by Receiver Operating Characteristics (ROC) analysis. Prognostic value of PET/CT metabolic parameters was assessed by Kaplan-Meier estimates of overall survival. Results Lesions were histologically documented in 40 patients: a sarcomatous transformation was found in 16, a dysplastic neurofibroma (NF) in 7, and a benign NF in 17; in the remaining 9 patients, a minimal follow-up of 12 mo (median 59 mo) confirmed the absence of transformation. The optimal cut off values for detection of malignant transformation were, in decreasing order of area under the ROC curves, a tumour-to-liver (T/L) ratio >2.5, SUVmax > 4.5, total lesion glycolysis (TLG) > 377, total metabolic tumour volume (TMTV) > 88 cm3, and heterogeneity index (HIsuv) > 1.69. The best prognostic marker was the TLG: the 4-y estimates of survival were 97% [95% CI, 90% - 100%] in patients with TLG ≤ 377 vs. 27% [95% CI, 5% - 49%] in patients with TLG > 377 (P < 0.0001; χ2 27.85; hazard ratio 13.27 [95% CI, 3.72–47.35]). T/L ratio, SUVmax and TMTV demonstrated slightly lower performance to predict survival, with χ2 ranging 14.41–19.12. The HIsuv index was not predictive of survival. Conclusion Our study demonstrates that TLG and TMTV, as PET/CT measures of metabolic tumour burden, may be used clinically to identify sarcomatous transformation in patients with NF1 and predict overall survival, with a higher specificity for the TLG. Conventional measures such as the SUVmax, and T/L ratio also demonstrate high prognostic value." @default.
• W2300936242 created "2016-06-24" @default.
• W2300936242 creator A5002307250 @default.
• W2300936242 creator A5007684263 @default.
• W2300936242 creator A5014172852 @default.
• W2300936242 creator A5018129015 @default.
• W2300936242 creator A5029037831 @default.
• W2300936242 creator A5057668291 @default.
• W2300936242 creator A5059956407 @default.
• W2300936242 creator A5073531160 @default.
• W2300936242 creator A5080378844 @default.
• W2300936242 creator A5085729205 @default.
• W2300936242 creator A5088208299 @default.
• W2300936242 date "2016-03-17" @default.
• W2300936242 modified "2023-09-27" @default.
• W2300936242 title "Metabolic Tumour Burden Measured by 18F-FDG PET/CT Predicts Malignant Transformation in Patients with Neurofibromatosis Type-1" @default.
• W2300936242 cites W1968775852 @default.
• W2300936242 cites W1972232210 @default.
• W2300936242 cites W1974265958 @default.
• W2300936242 cites W1975503931 @default.
• W2300936242 cites W1976932204 @default.
• W2300936242 cites W1990052355 @default.
• W2300936242 cites W1997887695 @default.
• W2300936242 cites W2005559502 @default.
• W2300936242 cites W2010590846 @default.
• W2300936242 cites W2010801314 @default.
• W2300936242 cites W2026686051 @default.
• W2300936242 cites W2048643924 @default.
• W2300936242 cites W2051528031 @default.
• W2300936242 cites W2054244628 @default.
• W2300936242 cites W2058726666 @default.
• W2300936242 cites W2063563316 @default.
• W2300936242 cites W2069963119 @default.
• W2300936242 cites W2075627595 @default.
• W2300936242 cites W2088783247 @default.
• W2300936242 cites W2089631910 @default.
• W2300936242 cites W2094063569 @default.
• W2300936242 cites W2098216041 @default.
• W2300936242 cites W2110496314 @default.
• W2300936242 cites W2113286019 @default.
• W2300936242 cites W2120006816 @default.
• W2300936242 cites W2135443950 @default.
• W2300936242 cites W2137036286 @default.
• W2300936242 cites W2146522808 @default.
• W2300936242 cites W2147583641 @default.
• W2300936242 cites W2154396771 @default.
• W2300936242 cites W2159705543 @default.
• W2300936242 cites W2162863689 @default.
• W2300936242 cites W2165496688 @default.
• W2300936242 cites W2167284308 @default.
• W2300936242 cites W2170946947 @default.
• W2300936242 cites W4253368897 @default.
• W2300936242 cites W4299926503 @default.
• W2300936242 doi "https://doi.org/10.1371/journal.pone.0151809" @default.
• W2300936242 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4795780" @default.
• W2300936242 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26987124" @default.
• W2300936242 hasPublicationYear "2016" @default.
• W2300936242 type Work @default.
• W2300936242 sameAs 2300936242 @default.
• W2300936242 citedByCount "20" @default.
• W2300936242 countsByYear W23009362422016 @default.
• W2300936242 countsByYear W23009362422017 @default.
• W2300936242 countsByYear W23009362422018 @default.
• W2300936242 countsByYear W23009362422019 @default.
• W2300936242 countsByYear W23009362422020 @default.
• W2300936242 countsByYear W23009362422021 @default.
• W2300936242 countsByYear W23009362422022 @default.
• W2300936242 crossrefType "journal-article" @default.
• W2300936242 hasAuthorship W2300936242A5002307250 @default.
• W2300936242 hasAuthorship W2300936242A5007684263 @default.
• W2300936242 hasAuthorship W2300936242A5014172852 @default.
• W2300936242 hasAuthorship W2300936242A5018129015 @default.
• W2300936242 hasAuthorship W2300936242A5029037831 @default.
• W2300936242 hasAuthorship W2300936242A5057668291 @default.
• W2300936242 hasAuthorship W2300936242A5059956407 @default.
• W2300936242 hasAuthorship W2300936242A5073531160 @default.
• W2300936242 hasAuthorship W2300936242A5080378844 @default.
• W2300936242 hasAuthorship W2300936242A5085729205 @default.
• W2300936242 hasAuthorship W2300936242A5088208299 @default.
• W2300936242 hasBestOaLocation W23009362421 @default.
• W2300936242 hasConcept C126322002 @default.
• W2300936242 hasConcept C126838900 @default.
• W2300936242 hasConcept C142724271 @default.
• W2300936242 hasConcept C143998085 @default.
• W2300936242 hasConcept C167135981 @default.
• W2300936242 hasConcept C207103383 @default.
• W2300936242 hasConcept C2775842073 @default.
• W2300936242 hasConcept C2778984943 @default.
• W2300936242 hasConcept C2989005 @default.
• W2300936242 hasConcept C31033888 @default.
• W2300936242 hasConcept C44249647 @default.
• W2300936242 hasConcept C50382708 @default.
• W2300936242 hasConcept C58471807 @default.
• W2300936242 hasConcept C71924100 @default.
• W2300936242 hasConcept C90924648 @default.
• W2300936242 hasConceptScore W2300936242C126322002 @default.
• W2300936242 hasConceptScore W2300936242C126838900 @default.
• W2300936242 hasConceptScore W2300936242C142724271 @default.

• next